DRMA

Dermata Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website dermatarx.com
Employees(FY) 8
ISIN US2498454055

Performance

-10.08%

-27.95%

-46.05%

-72.38%

-87.32%

YTD

-90.73%

Profile

Dermata Therapeutics, Inc., a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Advanced Technical Analysis

Technical Analysis of DRMA 2024-11-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward pressure, while the Oscillators Score of 53 suggests a neutral stance. The Technical Score of 31 further reinforces the bearish outlook, indicating that caution is warranted in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of DRMA

Stock Rank

Recent News & Updates

2024-11-14 19:35
Life Sciences Investor Forum: Presentations Now Available for Online Viewing(Yahoo Finance)
2024-11-13 03:15
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results(Accesswire)
2024-11-11 19:35
Life Sciences Investor Forum Agenda Announced for November 14th(Yahoo Finance)
2024-11-10 19:35
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024(Globenewswire)
2024-10-08 04:15
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024(Accesswire)
2024-09-17 05:15
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules(Accesswire)
2024-09-16 09:00
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules(Accesswire)
2024-09-05 04:05
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024(Accesswire)
2024-08-07 11:53
DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q2 2024(Investorplace)
2024-08-07 04:05
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results(Accesswire)
2024-07-16 21:00
Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne(Accesswire)
2024-05-16 20:30
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules(Accesswire)
2024-05-15 10:54
DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-15 04:05
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results(Accesswire)
2024-05-12 19:23
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday(Investorplace)
2024-04-02 19:00
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now(Globenewswire)
2024-04-01 19:00
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now(Globenewswire)
2024-03-27 04:05
Dermata to Present at the Emerging Growth Conference on April 3, 2024(Accesswire)
2024-03-21 10:53
DRMA Stock Earnings: Dermata Therapeutics Reported Results for Q4 2023(Investorplace)
2024-03-21 04:05
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results(Accesswire)
2024-02-06 18:00
Presenting on the Emerging Growth Conference 67 Day 2 on February 8 Register Now(Globenewswire)
2024-02-05 18:00
Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now(Globenewswire)
2024-01-31 20:00
Dermata to Present at the Emerging Growth Conference on February 7, 2024(Accesswire)
2024-01-04 19:31
Why Is Dermata Therapeutics (DRMA) Stock Up 62% Today?(Investorplace)
2024-01-04 03:05
Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis(Yahoo Finance)
2023-12-20 03:05
Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne(Yahoo Finance)
2023-11-16 20:06
Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug(Yahoo Finance)
2023-11-16 00:30
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules(Accesswire)
2023-11-15 19:00
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols(Accesswire)
2023-11-09 03:05
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results(Accesswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.